HCW Biologics (HCWB) fell nearly 11% in recent Monday trading after the company said it received a delisting notice from Nasdaq.
The company said it faces potential delisting following its failure to regain compliance with Nasdaq's requirements for continued listing. It was notified in June by exchange regulators that its market value of listed securities, or MVLS, was below the required $50 million threshold for 30 straight business days.
HCW Biologics said it intends to timely request a hearing before the Nasdaq Hearing Panel to avoid delisting and to discuss how it plans to regain compliance with the MVLS rule.
Price: 0.40, Change: -0.05, Percent Change: -10.91